Cargando…

Dental invasive procedures in von Willebrand disease outpatients treated with high purity FVIII/VWF complex concentrate (Fanhdi®): experience of a single center

PURPOSE: To retrospectively assess the effectiveness and safety of customized hemostatic protocols using a plasma-derived, von Willebrand Factor (VWF)-containing Factor VIII concentrate (pdVWF/FVIII) in von Willebrand disease (VWD) patients undergoing dental invasive procedures. METHODS: Protocol fo...

Descripción completa

Detalles Bibliográficos
Autores principales: De Padua, Valeria, Romeo, Umberto, Santoro, Cristina, Bosco, Riccardo, Baldacci, Erminia, Ferretti, Antonietta, Malaspina, Francesco, Mazzucconi, Maria Gabriella, Gaglioti, Domenico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044789/
https://www.ncbi.nlm.nih.gov/pubmed/32140581
http://dx.doi.org/10.1016/j.heliyon.2020.e03426
_version_ 1783501642069442560
author De Padua, Valeria
Romeo, Umberto
Santoro, Cristina
Bosco, Riccardo
Baldacci, Erminia
Ferretti, Antonietta
Malaspina, Francesco
Mazzucconi, Maria Gabriella
Gaglioti, Domenico
author_facet De Padua, Valeria
Romeo, Umberto
Santoro, Cristina
Bosco, Riccardo
Baldacci, Erminia
Ferretti, Antonietta
Malaspina, Francesco
Mazzucconi, Maria Gabriella
Gaglioti, Domenico
author_sort De Padua, Valeria
collection PubMed
description PURPOSE: To retrospectively assess the effectiveness and safety of customized hemostatic protocols using a plasma-derived, von Willebrand Factor (VWF)-containing Factor VIII concentrate (pdVWF/FVIII) in von Willebrand disease (VWD) patients undergoing dental invasive procedures. METHODS: Protocol for each patient was drawn up by the Blood Unit based on the VWD type, disease severity, and type of treatment. pdFVIII/VWF infusions and doses were registered at 30–60 min before intervention (t0) and at 12-24-36-48-72 h after intervention (t12-t72) and up to day 7. Any peri- or postoperative bleeding, complication or adverse event was registered. RESULTS: Forty-five dental procedures were performed on 20 VWD patients (six type-1, two type-2a, six type-2b, six type-3). Most pdFVIII/VWF infusions at t0 were 60 IU/kg (n = 7) and 50 IU/kg (n = 9). Subsequent infusions were mostly 30–50 IU/kg. No bleeding complications or adverse events were reported. CONCLUSION: This study supports the safety and efficacy of pdFVIII/VWF to prevent peri- and postoperative bleeding after invasive oral procedures.
format Online
Article
Text
id pubmed-7044789
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-70447892020-03-05 Dental invasive procedures in von Willebrand disease outpatients treated with high purity FVIII/VWF complex concentrate (Fanhdi®): experience of a single center De Padua, Valeria Romeo, Umberto Santoro, Cristina Bosco, Riccardo Baldacci, Erminia Ferretti, Antonietta Malaspina, Francesco Mazzucconi, Maria Gabriella Gaglioti, Domenico Heliyon Article PURPOSE: To retrospectively assess the effectiveness and safety of customized hemostatic protocols using a plasma-derived, von Willebrand Factor (VWF)-containing Factor VIII concentrate (pdVWF/FVIII) in von Willebrand disease (VWD) patients undergoing dental invasive procedures. METHODS: Protocol for each patient was drawn up by the Blood Unit based on the VWD type, disease severity, and type of treatment. pdFVIII/VWF infusions and doses were registered at 30–60 min before intervention (t0) and at 12-24-36-48-72 h after intervention (t12-t72) and up to day 7. Any peri- or postoperative bleeding, complication or adverse event was registered. RESULTS: Forty-five dental procedures were performed on 20 VWD patients (six type-1, two type-2a, six type-2b, six type-3). Most pdFVIII/VWF infusions at t0 were 60 IU/kg (n = 7) and 50 IU/kg (n = 9). Subsequent infusions were mostly 30–50 IU/kg. No bleeding complications or adverse events were reported. CONCLUSION: This study supports the safety and efficacy of pdFVIII/VWF to prevent peri- and postoperative bleeding after invasive oral procedures. Elsevier 2020-02-25 /pmc/articles/PMC7044789/ /pubmed/32140581 http://dx.doi.org/10.1016/j.heliyon.2020.e03426 Text en © 2020 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
De Padua, Valeria
Romeo, Umberto
Santoro, Cristina
Bosco, Riccardo
Baldacci, Erminia
Ferretti, Antonietta
Malaspina, Francesco
Mazzucconi, Maria Gabriella
Gaglioti, Domenico
Dental invasive procedures in von Willebrand disease outpatients treated with high purity FVIII/VWF complex concentrate (Fanhdi®): experience of a single center
title Dental invasive procedures in von Willebrand disease outpatients treated with high purity FVIII/VWF complex concentrate (Fanhdi®): experience of a single center
title_full Dental invasive procedures in von Willebrand disease outpatients treated with high purity FVIII/VWF complex concentrate (Fanhdi®): experience of a single center
title_fullStr Dental invasive procedures in von Willebrand disease outpatients treated with high purity FVIII/VWF complex concentrate (Fanhdi®): experience of a single center
title_full_unstemmed Dental invasive procedures in von Willebrand disease outpatients treated with high purity FVIII/VWF complex concentrate (Fanhdi®): experience of a single center
title_short Dental invasive procedures in von Willebrand disease outpatients treated with high purity FVIII/VWF complex concentrate (Fanhdi®): experience of a single center
title_sort dental invasive procedures in von willebrand disease outpatients treated with high purity fviii/vwf complex concentrate (fanhdi®): experience of a single center
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044789/
https://www.ncbi.nlm.nih.gov/pubmed/32140581
http://dx.doi.org/10.1016/j.heliyon.2020.e03426
work_keys_str_mv AT depaduavaleria dentalinvasiveproceduresinvonwillebranddiseaseoutpatientstreatedwithhighpurityfviiivwfcomplexconcentratefanhdiexperienceofasinglecenter
AT romeoumberto dentalinvasiveproceduresinvonwillebranddiseaseoutpatientstreatedwithhighpurityfviiivwfcomplexconcentratefanhdiexperienceofasinglecenter
AT santorocristina dentalinvasiveproceduresinvonwillebranddiseaseoutpatientstreatedwithhighpurityfviiivwfcomplexconcentratefanhdiexperienceofasinglecenter
AT boscoriccardo dentalinvasiveproceduresinvonwillebranddiseaseoutpatientstreatedwithhighpurityfviiivwfcomplexconcentratefanhdiexperienceofasinglecenter
AT baldaccierminia dentalinvasiveproceduresinvonwillebranddiseaseoutpatientstreatedwithhighpurityfviiivwfcomplexconcentratefanhdiexperienceofasinglecenter
AT ferrettiantonietta dentalinvasiveproceduresinvonwillebranddiseaseoutpatientstreatedwithhighpurityfviiivwfcomplexconcentratefanhdiexperienceofasinglecenter
AT malaspinafrancesco dentalinvasiveproceduresinvonwillebranddiseaseoutpatientstreatedwithhighpurityfviiivwfcomplexconcentratefanhdiexperienceofasinglecenter
AT mazzucconimariagabriella dentalinvasiveproceduresinvonwillebranddiseaseoutpatientstreatedwithhighpurityfviiivwfcomplexconcentratefanhdiexperienceofasinglecenter
AT gagliotidomenico dentalinvasiveproceduresinvonwillebranddiseaseoutpatientstreatedwithhighpurityfviiivwfcomplexconcentratefanhdiexperienceofasinglecenter